Michael Miller, ESC 2022: Icosapent ethyl for smoking, the REDUCE-IT study
The REDUCE-IT study evaluated the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the REDUCE-IT study and n–3 fatty acid supplementation.
The abstract entitled ‘Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- Could you give us a brief overview of the REDUCE-IT study and its overall findings? (0:31)
- Why do you think this trial had positive findings when other studies with n–3 fatty acid supplementation have failed? (2:06)
Disclosures: Michael Miller is a consultant for Amarin.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
Additional Resources: Miller M, Bhatt DL, Steg PG, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. 2022;pvac045. doi: 10.1093/ehjcvp/pvac045
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!